磁共振成像
磁共振造影剂
钆
螯合作用
核磁共振
纳米颗粒
生物相容性
材料科学
二聚体
丙烯酸
化学
纳米技术
单体
聚合物
放射科
医学
冶金
物理
作者
Zheyu Shen,Wenpei Fan,Zhèn Yáng,Yijing Liu,Vladimir I. Bregadze,Swadhin K. Mandal,Bryant C. Yung,Lisen Lin,Ting Liu,Wei Tang,Lingling Shan,Yuan Liu,Shoujun Zhu,Sheng Wang,Weijing Yang,L. Henry Bryant,Duong T. Nguyen,Aiguo Wu,Xiaoyuan Chen
出处
期刊:Small
[Wiley]
日期:2019-08-25
卷期号:15 (41): e1903422-e1903422
被引量:49
标识
DOI:10.1002/smll.201903422
摘要
Abstract Gd chelates have occupied most of the market of magnetic resonance imaging (MRI) contrast agents for decades. However, there have been some problems (nephrotoxicity, non‐specificity, and low r1) that limit their applications. Herein, a wet‐chemical method is proposed for facile synthesis of poly(acrylic acid) (PAA) stabilized exceedingly small gadolinium oxide nanoparticles (ES‐GON‐PAA) with an excellent water dispersibility and a size smaller than 2.0 nm, which is a powerful T1‐weighted MRI contrast agent for diagnosis of diseases due to its remarkable relaxivities (r1 = 70.2 ± 1.8 mM−1 s−1, and r2/r1 = 1.02 ± 0.03, at 1.5 T). The r1 is much higher and the r2/r1 is lower than that of the commercial Gd chelates and reported gadolinium oxide nanoparticles (GONs). Further ES‐GON‐PAA is developed with conjugation of RGD2 (RGD dimer) (i.e., ES‐GON‐PAA@RGD2) for T1‐weighted MRI of tumors that overexpress RGD receptors (i.e., integrin αvβ3). The maximum signal enhancement (ΔSNR) for T1‐weighted MRI of tumors reaches up to 372 ± 56% at 2 h post‐injection of ES‐GON‐PAA@RGD2, which is much higher than commercial Gd‐chelates (<80%). Due to the high biocompatibility and high tumor accumulation, ES‐GON‐PAA@RGD2 with remarkable relaxivities is a promising and powerful T1‐weighted MRI contrast agent.
科研通智能强力驱动
Strongly Powered by AbleSci AI